Becton Dickinson stock gains attention as margins and valuation draw analyst focus

Published on 09/19/2026 at 11:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Becton Dickinson stock closed at USD 180.94 on September 18, 2026, with a trailing YTD return of 20.90 percent. Analysts now see fair value near USD 225.00 and highlight FY2025 revenue of USD 21.8 billion and a 7.7 percent net margin.

Steriler Reinraum mit Mitarbeitern an der Produktionslinie für Medizinprodukte — Becton Dickinson betreibt moderne Reinraum Fertigungsanlagen für Medizinprodukte weltweit, ISIN US0718131099 NYSE, Illustration mit AI erstellt.

Becton, Dickinson and Company stock (ISIN US0718131099) closed at USD 180.94 on the New York Stock Exchange on September 18, 2026, only modestly below recent trading around USD 180.60 and carrying a year to date return of 20.90 percent per NYSE data cited by MarketWatch and Yahoo Finance.

Analysts lift fair value estimates and highlight margin strength

Fresh attention around Becton Dickinson stock is driven by updated valuation work that lifts the analyst fair value estimate from USD 216.80 to USD 225.00, pointing to roughly 19.6 percent implied upside versus the recent close of USD 180.94 on September 18, 2026, according to Simply Wall St on September 19, 2026.

The same overview notes that bullish analysts have raised price targets into the USD 190 to USD 210 range, reflecting higher confidence in Becton Dickinson margin potential, product quality and manufacturing scale, again against the backdrop of a last close around USD 180.94 on September 18, 2026, as reported by Simply Wall St on September 19, 2026.

Revenue growth and valuation context in diagnostics

In the broader medical diagnostics sector, Becton Dickinson continues to stand out on quantitative value metrics, with fiscal year 2025 revenue of USD 21.8 billion and a net income margin of 7.7 percent compared with revenue of USD 19.1 billion in fiscal year 2021, marking approximately 14 percent growth over four years according to Investing.com on September 18, 2026.

The same sector outlook describes Becton Dickinson trading at USD 180.60 as of September 18, 2026, 11:20 a.m. Eastern Time, with a stated fair value upside of 25.7 percent and an analyst consensus upside of 25.9 percent, alongside a price to earnings ratio of 29.7 times and year to date performance of 18.3 percent and a three month gain of 25.4 percent, as detailed by Investing.com on September 18, 2026.

Regulatory risks and margin comparisons remain important

Valuation tailwinds are balanced by regulatory and execution risks that investors continue to monitor. A recent comparison between Becton Dickinson and Thermo Fisher Scientific for the fiscal third quarter highlights that Becton Dickinson delivered revenue growth of 5.4 percent year on year and organic growth of 4.4 percent, but faced scrutiny related to its Alaris infusion system and recalls of contaminated sodium chloride ampules, as well as an FDA warning letter following a three week shipping hold on ChloraPrep and PurPrep products, according to Yahoo Finance on September 18, 2026.

Despite these regulatory headwinds, the same analysis points out that Becton Dickinson achieved an adjusted operating margin of 24.9 percent in that fiscal third quarter, compared with 22.8 percent for Thermo Fisher, illustrating that the company continues to convert its scale into margin strength even while addressing compliance issues, as discussed by Yahoo Finance on September 18, 2026.

Stock performance, valuation discount and investor perspective

From a performance standpoint, Becton Dickinson stock has delivered a trailing year to date total return of 20.90 percent versus 11.76 percent for the S&P 500 index as of September 18, 2026, underscoring that the shares have outpaced the broader market this year according to a total return overview on Yahoo Finance dated September 18, 2026.

At the same time, Simply Wall St notes that Becton Dickinson trades about 23 percent below one intrinsic value estimate and around 8 percent under the average analyst target, with one popular valuation narrative placing fair value near USD 195.67 slightly above the last close of roughly USD 181, which keeps the discount in focus while also emphasizing that Alaris related regulatory scrutiny and execution risk around separating Biosciences and Diagnostic Solutions could derail the upside case, as outlined by Simply Wall St on September 18, 2026.

Current price level and trading venue

As of the last completed trading day on September 18, 2026, Becton Dickinson stock closed at USD 180.94 on the New York Stock Exchange, down 0.24 percent from a previous close of USD 181.38, with intraday trading having taken place between an open of USD 179.76 and that closing level and with the shares also quoted after hours at USD 180.94, per NYSE data relayed by Yahoo Finance on September 18, 2026.